KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding
Others
Ratios

AbCellera Biologics (ABCL) Income towards Parent Company (2020 - 2023)

Historic Income towards Parent Company for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.

  • AbCellera Biologics' Income towards Parent Company fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$47.2 million, marking a year-over-year increase of 6348.95%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
  • AbCellera Biologics' Income towards Parent Company amounted to -$47.2 million in Q4 2023, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Income towards Parent Company registered a high of $168.6 million during Q1 2022, and its lowest value of -$47.2 million during Q4 2023.
  • Over the past 4 years, AbCellera Biologics' median Income towards Parent Company value was -$2.5 million (recorded in 2020), while the average stood at $20.5 million.
  • Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Income towards Parent Company was 570062.11% (2021), while the steepest drop was 69391.01% (2021).
  • Over the past 4 years, AbCellera Biologics' Income towards Parent Company (Quarter) stood at $161.2 million in 2020, then tumbled by 62.8% to $59.9 million in 2021, then crashed by 149.86% to -$29.9 million in 2022, then tumbled by 57.73% to -$47.2 million in 2023.
  • Its Income towards Parent Company stands at -$47.2 million for Q4 2023, versus -$28.6 million for Q3 2023 and -$30.5 million for Q2 2023.